Project dates: September 2016 - Julye 2022
Principal Investigator: Marks K
Four times as prevalent in the US as HIV infection, hepatitis C is already the leading cause of liver failure and liver transplantation, the disease burden and health care costs will continue to rise in the coming decades, and the 1.5-2.0 million people who inject illicit drugs are the most severely affected. This study will examine the feasibility, acceptability, safety, effectiveness, and cost of an Accessible Care intervention for engaging people who inject illicit drugs in hepatitis C care. To end the hepatitis C epidemic, data are needed on effective methods to provide successful antiviral therapy to the core population affected by the epidemic.Abstract on NIH RePORTER
Medical provider stigma experienced by people who use drugs (MPS-PWUD): Development and validation of a scale among people who currently inject drugs in New York City
Drug and Alcohol Dependence, 221, 108589. doi: 10.1016/j.drugalcdep.2021.108589. PMCID: PMC8029599.